Molecular Partners Ag -adr logo

Molecular Partners Ag -adr Share Price Today

(NASDAQ: MOLN)

Molecular Partners Ag -adr share price is $4.9 & ₹426.15 as on 6 Mar 2025, 2.30 'hrs' IST

$4.9

▲

0.22

(4.7%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Molecular Partners Ag -adr share price in Dollar and Rupees. Guide to invest in Molecular Partners Ag -adr stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Molecular Partners Ag -adr, along with analyst recommendations, forecasts, and comprehensive financials.

Molecular Partners Ag -adr share price movements

  • Today's Low: $4.61
    Today's High: $4.98

    Day's Volatility :7.43%

  • 52 Weeks Low: $3.32
    52 Weeks High: $12.70

    52 Weeks Volatility :73.86%

Molecular Partners Ag -adr (MOLN) Returns

PeriodMolecular Partners Ag -adrSector (Health Care)Index (Russel 2000)
3 Months
-15.66%
3.7%
0.0%
6 Months
-15.3%
-2.8%
0.0%
1 Year
16.67%
2.5%
0.0%
3 Years
-78.47%
12.9%
-11.6%

Molecular Partners Ag -adr (MOLN) Key Statistics

in dollars & INR

Previous Close
$4.68
Open
$4.61
Today's High
$4.98
Today's Low
$4.61
Market Capitalization
$172.5M
Today's Volume
$3.2K
52 Week High
$12.7
52 Week Low
$3.32
Revenue TTM
$6.0M
EBITDA
$-62.2M
Earnings Per Share (EPS)
$-1.95
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-37.37%

How to invest in Molecular Partners Ag -adr Stock (MOLN) from India?

It is very easy for Indian residents to invest directly in Molecular Partners Ag -adr from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Molecular Partners Ag -adr stock in both Indian Rupees (INR) and US Dollars (USD). Search for Molecular Partners Ag -adr or MOLN on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Molecular Partners Ag -adr or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Molecular Partners Ag -adr shares which would translate to 0.177 fractional shares of Molecular Partners Ag -adr as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Molecular Partners Ag -adr, in just a few clicks!

Returns in Molecular Partners Ag -adr (MOLN) for Indian investors in Rupees

The Molecular Partners Ag -adr stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Molecular Partners Ag -adr investment value today

Current value as on today

₹1,21,616

Returns

₹21,616

(+21.62%)

Returns from Molecular Partners Ag -adr Stock

₹16,667 (+16.67%)

Dollar Returns

₹4,949 (+4.95%)

Indian investors sentiment towards Molecular Partners Ag -adr (MOLN)

-17%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Molecular Partners Ag -adr Stock from India on INDmoney has decreased by -17% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Molecular Partners Ag -adr

  • Suvretta Capital Management, LLC

    6.03%

  • Bvf Inc

    3.67%

  • UBS Group AG

    0.02%

Analyst Recommendation on Molecular Partners Ag -adr

Sell

    9%Buy

    27%Hold

    63%Sell

Based on 11 Wall street analysts offering stock ratings for Molecular Partners Ag -adr(by analysts ranked 0 to 5 stars)

Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
1
1
1
Hold
3
3
3
Sell
7
7
7

Analyst Forecast on Molecular Partners Ag -adr Stock (MOLN)

What analysts predicted

Upside of 116.14%

Target:

$10.59

Current:

$4.90

Insights on Molecular Partners Ag -adr Stock (Ticker Symbol: MOLN)

  • Price Movement

    In the last 3 years, MOLN stock has moved down by -79.6%

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 2.73M → 681.0K (in $), with an average decrease of 49.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -11.32M → -16.40M (in $), with an average decrease of 21.0% per quarter

  • MOLN vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 66.5% return, outperforming this stock by 49.8%

  • MOLN vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 51.6% return, outperforming this stock by 131.2%

  • Price to Sales

    ForMOLN every $1 of sales, investors are willing to pay $26.9, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.2 for every $1 of sales.

MOLN Molecular Partners Ag -adr Financials in INR & Dollars

FY18Y/Y Change
Revenue
$10.4M
↓ 48.27%
Net Income
$-37.3M
↑ 45.64%
Net Profit Margin
-357.66%
↓ 230.61%
FY19Y/Y Change
Revenue
$20.7M
↑ 96.84%
Net Income
$-36.9M
↓ 2.02%
Net Profit Margin
-178.03%
↑ 179.63%
FY20Y/Y Change
Revenue
$10.5M
↓ 54.16%
Net Income
$-70.6M
↑ 72.96%
Net Profit Margin
-671.7%
↓ 493.67%
FY21Y/Y Change
Revenue
$10.1M
↓ 0.15%
Net Income
$-69.3M
↑ 1.63%
Net Profit Margin
-683.65%
↓ 11.95%
FY22Y/Y Change
Revenue
$203.1M
↑ 1931.68%
Net Income
$126.3M
↓ 284.77%
Net Profit Margin
62.17%
↑ 745.82%
FY23Y/Y Change
Revenue
$8.1M
↓ 96.29%
Net Income
$-71.7M
↓ 152.59%
Net Profit Margin
-880.7%
↓ 942.87%
Q2 FY23Q/Q Change
Revenue
$460.9K
↓ 86.39%
Net Income
$-17.8M
↑ 4.33%
Net Profit Margin
-3.9K%
↓ 3349.9%
Q3 FY23Q/Q Change
Revenue
$2.8M
↑ 512.29%
Net Income
$-12.7M
↓ 28.45%
Net Profit Margin
-450.18%
↑ 3402.11%
Q4 FY23Q/Q Change
Revenue
$1.2M
↓ 59.39%
Net Income
$-22.9M
↑ 72.92%
Net Profit Margin
-1.9K%
↓ 1466.49%
Q1 FY24Q/Q Change
Revenue
$3.1M
↑ 165.31%
Net Income
$-12.7M
↓ 42.75%
Net Profit Margin
-413.62%
↑ 1503.05%
Q2 FY24Q/Q Change
Revenue
$1.7M
↓ 43.35%
Net Income
$-16.9M
↑ 33.17%
Net Profit Margin
-972.4%
↓ 558.78%
Q3 FY24Q/Q Change
Revenue
$681.0K
↓ 56.09%
Net Income
$-16.4M
↑ 8.77%
Net Profit Margin
-2.4K%
↓ 1436.41%
FY18Y/Y Change
Profit
$-5.3M
↓ 339.15%
FY19Y/Y Change
Profit
$-23.5M
↑ 340.54%
FY20Y/Y Change
Profit
$-52.6M
↑ 102.17%
FY21Y/Y Change
Profit
$-50.4M
↓ 0.73%
FY22Y/Y Change
Profit
$148.7M
↓ 399.23%
FY23Y/Y Change
Profit
$-47.2M
↓ 129.4%
Q2 FY23Q/Q Change
Profit
$-12.5M
↑ 16.3%
Q3 FY23Q/Q Change
Profit
$-10.1M
↓ 19.18%
Q4 FY23Q/Q Change
Profit
$-12.6M
↑ 19.99%
Q1 FY24Q/Q Change
Profit
$-12.8M
↑ 4.49%
Q2 FY24Q/Q Change
Profit
$-12.9M
↑ 1.5%
Q3 FY24Q/Q Change
Profit
$681.0K
↓ 105.9%
FY18Y/Y Change
Operating Cash Flow
$-42.8M
↑ 6.13%
Investing Cash Flow
$9.7M
↓ 53.93%
Financing Cash Flow
$395.1K
↓ 50.94%
FY19Y/Y Change
Operating Cash Flow
$-1.2M
↓ 97.2%
Investing Cash Flow
$-20.2M
↓ 306.35%
Financing Cash Flow
$-230.9K
↓ 157.91%
FY20Y/Y Change
Operating Cash Flow
$-32.6M
↑ 2337.59%
Investing Cash Flow
$-24.5M
↑ 9.63%
Financing Cash Flow
$127.3M
↓ 49968.72%
FY21Y/Y Change
Operating Cash Flow
$-98.8M
↑ 213.81%
Investing Cash Flow
$-24.2M
↑ 2.26%
Financing Cash Flow
$54.9M
↓ 55.32%
FY22Y/Y Change
Operating Cash Flow
$127.1M
↓ 230.36%
Investing Cash Flow
$-108.4M
↑ 354.74%
Financing Cash Flow
$-1.7M
↓ 103.1%
Q2 FY23Q/Q Change
Operating Cash Flow
$-14.7M
↓ 19.72%
Investing Cash Flow
$4.5M
↑ 0.0%
Financing Cash Flow
$-304.3K
↓ 7.74%
Q3 FY23Q/Q Change
Operating Cash Flow
$-14.7M
↓ 0.67%
Investing Cash Flow
$19.8M
↑ 340.5%
Financing Cash Flow
$-331.6K
↑ 8.76%

Molecular Partners Ag -adr Technicals Summary

Sell

Neutral

Buy

Molecular Partners Ag -adr is currently in a neutral trading position according to technical analysis indicators.

Molecular Partners Ag -adr (MOLN) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Molecular Partners Ag -adr logo
Molecular Partners Ag -adr
-2.78%
-15.3%
16.67%
-78.47%
-74.31%
Regeneron Pharmaceuticals, Inc. logo
Regeneron Pharmaceuticals, Inc.
-1.42%
-40.28%
-29.31%
11.08%
44.83%
Beone Medicines Ltd logo
Beone Medicines Ltd
17.63%
36.87%
64.37%
45.89%
71.3%
Vertex Pharmaceuticals Incorporated logo
Vertex Pharmaceuticals Incorporated
1.94%
4.92%
19.37%
108.73%
123.83%
Alnylam Pharmaceuticals, Inc. logo
Alnylam Pharmaceuticals, Inc.
-8.03%
-0.89%
66.53%
52.9%
126.66%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Molecular Partners Ag -adr logo
Molecular Partners Ag -adr
1.71
NA
NA
-1.6
-0.37
-0.21
NA
4.18
Regeneron Pharmaceuticals, Inc. logo
Regeneron Pharmaceuticals, Inc.
17.86
17.86
1.01
43.09
0.16
0.07
0.01
273.57
Beone Medicines Ltd logo
Beone Medicines Ltd
NA
NA
NA
1.43
-0.19
-0.06
NA
31.22
Vertex Pharmaceuticals Incorporated logo
Vertex Pharmaceuticals Incorporated
32.84
NA
1.34
18.07
-0.03
0.13
NA
63.87
Alnylam Pharmaceuticals, Inc. logo
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
0.57
-15.01
-0.03
NA
0.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Molecular Partners Ag -adr logo
Molecular Partners Ag -adr
Sell
$172.5M
-74.31%
1.71
0.0%
Regeneron Pharmaceuticals, Inc. logo
Regeneron Pharmaceuticals, Inc.
Buy
$73.8B
44.83%
17.86
31.07%
Beone Medicines Ltd logo
Beone Medicines Ltd
NA
$29.1B
71.3%
NA
-16.92%
Vertex Pharmaceuticals Incorporated logo
Vertex Pharmaceuticals Incorporated
Buy
$124.9B
123.83%
32.84
-4.86%
Alnylam Pharmaceuticals, Inc. logo
Alnylam Pharmaceuticals, Inc.
Buy
$31.4B
126.66%
NA
-12.37%

About Molecular Partners Ag -adr

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Organization
Molecular Partners Ag -adr
Employees
167
CEO
Dr. Patrick Amstutz Ph.D.
Industry
Services

Management People of Molecular Partners Ag -adr

NameTitle
Dr. Patrick Amstutz Ph.D.
Co-Founder, CEO, Member of Management Board & Director
Dr. Michael Tobias Stumpp Ph.D.
Co-Founder, Executive VP of Projects & Member of Management Board
Mr. Robert Hendriks
Senior VP of Finance
Mr. Alexander Zurcher
COO & Member of Management Board
Ms. Renate Gloggner
Executive VP of People & Community and Member of Management Board
Mr. Philippe Legenne M.B.A., M.D.
Chief Medical Officer & Member of the Management Board
Mr. Daniel Steiner Ph.D.
Senior Vice President of Research & Technology
Mr. Seth D. Lewis
Senior Vice President of Investor Relations, Communications & Strategy
Mr. Michael Pitzner
General Counsel, Compliance Officer, Senior VP Legal & Business Development
Dr. Pamela A. Trail Ph.D.
Strategic Consultant

Important FAQs about investing in MOLN Stock from India :

What is Molecular Partners Ag -adr share price today?

Molecular Partners Ag -adr share price today stands at $4.90, Open: $4.61 ; Previous Close: $4.68 ; High: $4.98 ; Low: $4.61 ; 52 Week High: $12.70 ; 52 Week Low: $3.32.

The stock opens at $4.61, after a previous close of $4.68. The stock reached a daily high of $4.98 and a low of $4.61, with a 52-week high of $12.70 and a 52-week low of $3.32.

Can Indians buy Molecular Partners Ag -adr shares?

Yes, Indians can invest in the Molecular Partners Ag -adr (MOLN) from India.

With INDmoney, you can buy Molecular Partners Ag -adr at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Molecular Partners Ag -adr at zero transaction cost.

How can I buy Molecular Partners Ag -adr shares from India?

It is very easy to buy Molecular Partners Ag -adr from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Molecular Partners Ag -adr (MOLN) be purchased?

Yes, you can buy fractional shares of Molecular Partners Ag -adr with INDmoney app.

What are the documents required to start investing in Molecular Partners Ag -adr stocks?

To start investing in Molecular Partners Ag -adr, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Molecular Partners Ag -adr Stock (MOLN)?

Today’s highest price of Molecular Partners Ag -adr (MOLN) is $4.98.

Today’s lowest price of Molecular Partners Ag -adr (MOLN) is $4.61.

What is today's market capitalisation of Molecular Partners Ag -adr?

Today's market capitalisation of Molecular Partners Ag -adr MOLN is 172.5M

What is the 52 Week High and Low Range of Molecular Partners Ag -adr Stock (MOLN)?

  • 52 Week High

    $12.70

  • 52 Week Low

    $3.32

What are the historical returns of Molecular Partners Ag -adr (MOLN)?

  • 1 Month Returns

    -2.78%

  • 3 Months Returns

    -15.3%

  • 1 Year Returns

    16.67%

  • 5 Years Returns

    -74.31%

Who is the Chief Executive Officer (CEO) of Molecular Partners Ag -adr ?

Dr. Patrick Amstutz Ph.D. is the current Chief Executive Officer (CEO) of Molecular Partners Ag -adr.